社区

与默克合作销售的卵巢癌药物 Lynparza 于2018年获得标签扩展纳入美国乳腺癌患者。该药物销售额在2018Q4连续增长23.7%，达到2.09亿美元。Tagrisso 销售额为5.94亿美元，比去年增长近一倍。 $阿斯利康(AZN)$

AstraZeneca plc AZN beat the Zacks Consensus Estimate for both earnings and sales in the fourth quarter of 2018. Pascal Soriot, AstraZeneca’s chief executive officer, said “AstraZeneca has returned to growth” as its product sales grew for two consecutive quarters, Per Soriot, 2019 will be marked by successful pipeline progress and commercial initiatives. The stock rose 5.4% in pre-market trading on Feb 14.

阿斯利康公司在2018年第四季度的收益和销售额都超过了 Zacks 共识估计。阿斯利康首席执行官帕斯卡尔•索利奥特表示，随着产品销量连续两个季度增长，“阿斯利康已恢复增长”，佩罗索洛特2019年将以成功的管道进度和商业举措为标志。2月14日，该股在上市前交易中上涨了5.4%。

This year so far, AstraZeneca’s shares have declined 4.9% against the industry’s increase of 2.2%.

今年迄今为止，阿斯利康股价已下跌4.9%，而该行业的涨幅为2.2%。

Fourth-quarter 2018 core earnings of 79 cents per American Depositary Share (“ADS”) beat the Zacks Consensus Estimate of 73 cents. Core earnings per share of $1.58 increased 22% year over year at constant exchange rates (“CER”), benefiting from higher revenues and operating profit.

2018年第四季度，美国存托股票（ ADS ）每股79美分的核心收益超过了 Zacks 共识预测的73美分。核心每股收益为1.58美元，按固定汇率计算，同比增长22%，受益于更高的收入和营业利润。

Total revenues were up 14% at CER to $6.4 billion in the reported quarter. Revenues also beat the Zacks Consensus Estimate of $6.16 billion.

在报告的季度，CER 的总收入增长了14%，达到64亿美元。收入也超过了 Zacks 一致估计的66.6亿美元。

All growth rates mentioned below are on a year-over-year basis and at CER.

以下所述的所有增长率均按年计算，并按中央应急循环基金计算。

产品销售上升

Product sales rose 8% at CER in the quarter to $5.77 billion. Higher sales of newer medicines, particularly cancer drugs, and strong performance in emerging markets, mainly China, offset lower sales of many other legacy medicines and drove product sales growth.

该季度 CER 的产品销售额增长了8%，达到57.7亿美元。较新药物（尤其是癌症药物）销量增加，新兴市场（主要是中国）表现强劲，抵消了许多其他遗留药物销量下降的影响，推动了产品销售增长。

Externalization revenues were up more than twofold from the year-ago period to $649. These revenues are generated from AstraZeneca’s externalization agreements.

对外收支收入比上年同期增加了两倍多，达到649美元。这些收入来自阿斯利康（AstraZeneca）的外部化协议。

Among AstraZeneca’s various therapeutic areas, Oncology was up 61%, New Cardiovascular, Renal and Metabolism (“CVRM”) was up 11% and Respiratory rose 5%. However, other medicines declined 21%.

在阿斯利康的各个治疗领域中，肿瘤治疗增长了61%，新心血管、肾脏和新陈代谢（“ CVRM ”）增长了11%，呼吸增长了5%。然而，其他药物下降了21%。